开放标签、多中心、随机、生物标志物整合伞式试验用于晚期胃癌二线治疗:K-Umbrella胃癌研究
该研究在8家韩国癌症中心筛查HER2阴性晚期胃癌患者的可成药靶点,按4:1随机分配至生物标志物组或对照组,比较靶向药联合紫杉醇与标准治疗的疗效。生物标志物组与对照组中位无进展生存期分别为3.7个月和4.0个月,中位总生存期分别为8.6个月和8.7个月,生物标志物组未显示更优生存,但基于免疫组化筛选和分配的伞式设计可行。
要点
- 生物标志物组与对照组中位无进展生存期分别为3.7个月和4.0个月,中位总生存期分别为8.6个月和8.7个月。
- EGFR 3+患者加用阿法替尼较标准治疗显示边际生存获益(无进展生存期4.0个月对2.2个月,P=0.09)。
- GSK2636771未延长PTEN缺失患者的生存,纳武利尤单抗组中位总生存期12.0个月对7.6个月(P=0.08)。
核心结论
- 生物标志物组未显示优于对照组的生存,但基于免疫组化筛选和分配的伞式设计对于新型药物的有效早期筛查是可行的。
研究设计与样本
- 开放标签、多中心、随机、生物标志物整合伞式试验,自8家韩国癌症中心筛查HER2阴性晚期胃癌患者。
- 采用免疫组化和原位杂交筛查可成药靶点,按4:1比例随机分配至生物标志物组或对照组。
- 生物标志物组接受特定靶向药联合紫杉醇:EGFR 2+/3+患者接受泛ERBB抑制剂阿法替尼(EGFR队列),PTEN缺失/缺失患者接受PIK3Cβ抑制剂GSK2636771(PTEN队列),PD-L1+、错配修复缺陷/微卫星高度不稳定或EB病毒相关病例接受抗PD-1抑制剂纳武利尤单抗(NIVO队列)。
- 生物标志物组无 predefined 生物标志物的NONE队列和对照组接受标准治疗(紫杉醇联合或不联合雷莫西尤单抗)。
- 共318例患者随机分配至对照组(n=64)和生物标志物组(n=254;EGFR n=67;PTEN n=37;NIVO n=48;NONE n=102),中位随访35个月。
主要发现
- 生物标志物组中位无进展生存期为3.7个月(95%CI 3.1至4.1),对照组为4.0个月(95%CI 3.0至4.6)。
- 生物标志物组中位总生存期为8.6个月(95%CI 7.6至9.8),对照组为8.7个月(95%CI 7.1至9.9)。
- EGFR 3+患者加用阿法替尼较标准治疗显示边际生存获益(无进展生存期4.0个月对2.2个月;P=0.09)。
- GSK2636771未延长PTEN缺失患者的生存。
- 加用纳武利尤单抗显示持久生存获益(中位总生存期12.0个月对7.6个月;P=0.08)。
关键数值与推荐
- 主要终点为无进展生存期,次要终点为疗效和安全性。
- 生物标志物组与对照组中位无进展生存期分别为3.7个月和4.0个月,中位总生存期分别为8.6个月和8.7个月。
- EGFR 3+患者阿法替尼联合紫杉醇较标准治疗:无进展生存期4.0个月对2.2个月,P=0.09。
- 纳武利尤单抗联合紫杉醇较标准治疗:中位总生存期12.0个月对7.6个月,P=0.08。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to screen targeted agents as second-line treatment with a standard-of-care (SOC) controlled umbrella trial design in advanced gastric cancer (AGC). PATIENTS AND METHODS: Patients with HER2-negative AGC from eight Korean cancer centers were screened for druggable targets using immunohistochemistry (IHC) and in situ hybridization, and randomly assigned to the biomarker versus control group at a 4:1 ratio. In the biomarker group, patients were treated with specific targeted agent plus paclitaxel: pan-ERBB inhibitor for epidermal growth factor receptor (EGFR) 2+/3+ patients (afatinib; EGFR cohort), PIK3Cβ inhibitor for phosphatase and tensin homolog (PTEN) loss/null patients (GSK2636771; PTEN cohort), and anti-PD-1 inhibitor for PD-L1+, deficient mismatch repair/microsatellite instability-high, or Epstein-Barr virus-related cases (nivolumab; NIVO cohort). NONE cohort in the biomarker group without predefined biomarkers and control group received SOC (paclitaxel with or without ramucirumab). The primary end point was progression-free survival (PFS), and the secondary end points were efficacy and safety. RESULTS: A total of 318 patients were randomly assigned into the control (n = 64) and biomarker (n = 254; EGFR, n = 67; PTEN, n = 37; NIVO, n = 48; NONE, n = 102) groups. Median follow-up was 35 months. Median PFS and overall survival (OS) were 3.7 (95% CI, 3.1 to 4.1) and 8.6 (95% CI, 7.6 to 9.8) months in the biomarker group and 4.0 (95% CI, 3.0 to 4.6) and 8.7 (95% CI, 7.1 to 9.9) months in the control group. Afatinib addition led to marginal survival benefits to patients with EGFR 3+ compared with SOC (PFS, 4.0 v 2.2 months; P = .09), but GSK2636771 did not prolong the survival of patients with PTEN loss. Addition of nivolumab showed a durable survival benefit (median OS, 12.0 v 7.6 months; P = .08). CONCLUSION: Although biomarker group did not show better survival than the control group, IHC-based screening and allocation of patients with AGC to the second-line treatment in an umbrella design were feasible for effective early screening of novel agents.
引用
- Lee CK, Kim HS, Jung M, et al. Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. J Clin Oncol. 2023. PMID: 37883723. doi:10.1200/JCO.23.00971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。